Fetal Retinoid Syndrome
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Fetal Retinoid Syndrome

What is the definition of Fetal Retinoid Syndrome?
Fetal retinoid syndrome is a characteristic pattern of physical birth defects in a baby that has been exposed to retinoids during pregnancy. The best-known retinoid is isotretinoin (Accutane), a drug used to treat severe cystic acne. Babies exposed to retinoids during pregnancy may have a wide variety of symptoms. Some may have no symptoms at all, others may have only intellectual and learning problems, while others will have very severe symptoms. Birth defects associated with retinoid exposure include: • Growth delay • Excess fluid around the brain (hydrocephalus) • Abnormally small head size (microcephaly) • Intellectual and learning disabilities • Ear and eye abnormalities • A split in the roof of the mouth (cleft palate) and other facial differences • Heart defects. It is thought that 20-35% of fetuses exposed to retinoids during pregnancy will develop some of these birth defects. Retinoids can cause these birth defects in the early weeks of pregnancy, even before a woman knows that she is pregnant. Some of the birth defects associated with Fetal retinoid syndrome may be diagnosed by ultrasound during pregnancy. Currently, public health programs exist to help reduce the chance that a woman will use retinoids if she is considering getting pregnant.
What are the alternative names for Fetal Retinoid Syndrome?
  • Fetal retinoid syndrome
  • Accutane fetal effects of
  • Accutane-exposed pregnancies
  • Acutane embryopathy
  • Isotretinoin (RoAccutane) embryopathy
  • Isotretinoin embryopathy
  • Isotretinoin fetal effects of
  • Isotretinoin teratogen syndrome
Who are the top Fetal Retinoid Syndrome Local Doctors?
Elite in Fetal Retinoid Syndrome
Elite in Fetal Retinoid Syndrome
Referral may be required
Jerusalem, JM, IL 

Abraham Fainsod practices practicing medicine in Jerusalem, Israel. Mr. Fainsod is rated as an Elite expert by MediFind in the treatment of Fetal Retinoid Syndrome. He is also highly rated in 2 other conditions, according to our data. His clinical expertise encompasses Fetal Retinoid Syndrome, Fetal Alcohol Syndrome (FAS), Campomelic Dysplasia, and Campomelia Cumming Type.

Distinguished in Fetal Retinoid Syndrome
Distinguished in Fetal Retinoid Syndrome
Referral may be required

Telehealth Video Visit

111 Michigan Avenue Northwest, Childrens National Telemedicine, 
Washington, DC 
Experience:
21+ years
Languages Spoken:
English
Offers Telehealth

Leslie Castelo-Soccio, MD, PhD, is a dermatologist at Children's National Hospital and professor of Pediatrics and Dermatology at the George Washington University School of Medicine and Health Sciences. She is an expert in hair disorders most notably alopecia areata as well as other autoimmune skin diseases. Her interests and expertise include hair, genetic skin disorders, neonatal dermatology, inflammatory skin diseases such as eczema/atopic dermatitis and psoriasis, pigmented lesions (moles), acne and vascular disorders. She is an expert in laser and surgical treatment for pediatric patients and provides services in the clinic and operating room. Dr. Castelo-Soccio has built a research career in alopecia and inflammatory skin disease and runs clinical trials on these diseases at Children's National. Dr. Castelo-Soccio has published extensively including peer-reviewed articles and book chapters on pediatric and medical dermatology. She is a national and international speaker on hair disorders and autoimmune skin disease. She is a member of the board of directors of the American Hair Research Association and has worked closely as a volunteer for the National Alopecia Areata Foundation and the Pediatric Dermatology Research Alliance. Dr. Castelo-Soccio received her bachelor's degree with honors in biological sciences from Harvard University and her MD and PhD from Cornell University - Weill Medical College. She completed residency training in dermatology at the University of Pennsylvania and her fellowship training in pediatric dermatology at the Children's Hospital of Philadelphia. She is board certified in dermatology and pediatric dermatology. From 2011-2021 she was an attending physician at Children's Hospital of Philadelphia. From 2021-2025 she was an attending physician and researcher at the National Institutes of Health, where she still serves as a special volunteer. Dr. Castelo is rated as a Distinguished provider by MediFind in the treatment of Fetal Retinoid Syndrome. She is also highly rated in 28 other conditions, according to our data. Her clinical expertise encompasses Autosomal Recessive Hypotrichosis, Alopecia Areata, Lamellar Ichthyosis, and Nonbullous Congenital Ichthyosiform Erythroderma. Dr. Castelo is board certified in American Board Of Dermatology, 2012 and Dermatology: American Board Of Dermatology, 2009.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Fetal Retinoid Syndrome
Distinguished in Fetal Retinoid Syndrome
Referral required

Office

1625 Straits Tpke Ste 306, 
Middlebury, CT 
Languages Spoken:
English

Christopher Bunick is a Dermatologist practicing medicine in Middlebury, Connecticut. Dr. Bunick is rated as a Distinguished provider by MediFind in the treatment of Fetal Retinoid Syndrome. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Lamellar Ichthyosis, Nonbullous Congenital Ichthyosiform Erythroderma, Acne, and Atopic Dermatitis.

What are the latest Fetal Retinoid Syndrome Clinical Trials?
The Impact of COVID-19 on Maternal and Neonatal Outcomes

Summary: The novel coronavirus (SARS-CoV-2) infection (COVID-19) has caused a worldwide pandemic. There is still much that is unknown regarding the virus, especially its effects on pregnancy, the fetus, and the neonate. This study seeks to evaluate adverse pregnancy and neonatal outcomes related to COVID-19 infection. The FDA has authorized emergency use authorization for the SARS-CoV-2 messenger ribonucle...

Match to trials
Find the right clinical trials for you in under a minute
Get started
The Cancer of the Pancreas Screening-5 CAPS5)Study

Summary: Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center